Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
Open accessThe DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Context: Cushing disease, a chronic hypercortisolism disorder, is associated with considerable morbidity and mortality. Normalizing cortisol production is the primary treatment goal. Objective: We aimed to evaluate the safety and efficacy of osilodrostat, a potent, orally available 11βhydroxylase inhibitor, compared with placebo in patients with Cushing disease. Methods: LINC 4 was a phase III, multicenter trial comprising an initial 12-week, randomized, double-blind, placebo-controlled (osilodrostat:placebo, 2:1) period followed by a 36-week, open-label treatment period (NCT02697734). Adult patients (aged 18-75 years) with confirmed Cushing disease and mean urinary free cortisol (mUFC) excretion ≥ 1.3 times the upper limit of normal (ULN) were eligible. The primary endpoint was the proportion of randomized patients with mUFC ≤ ULN at week 12. The key secondary endpoint was the proportion achieving mUFC ≤ ULN at week 36 (after 24 weeks’ open-label osilodrostat). Results: Seventy-three patients (median age, 39 years [range, 19-67]; mean/median mUFC, 3.1 × ULN/2.5 × ULN) received randomized treatment with osilodrostat (n = 48) or placebo (n = 25). At week 12, significantly more osilodrostat (77%) than placebo (8%) patients achieved mUFC ≤ ULN (odds ratio 43.4; 95% CI 7.1, 343.2; P < 0.0001). Response was maintained at week 36, when 81% (95% CI 69.9, 89.1) of all patients achieved mUFC ≤ ULN. The most common adverse events during the placebo-controlled period (osilodrostat vs placebo) were decreased appetite (37.5% vs 16.0%), arthralgia (35.4% vs 8.0%), and nausea (31.3% vs 12.0%). Conclusion: Osilodrostat rapidly normalized mUFC excretion in most patients with Cushing disease and maintained this effect throughout the study. The safety profile was favorable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The restoration of cortisol circadian rhythm following medical therapy has not been investigated or established for most medications used to treat CS, and it is not routinely measured to determine treatment response (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [134]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mean UFC is routinely used in clinical practice and research to monitor disease control and treatment response in patients with CS treated with medical therapy (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In clinical trials, the efficacy of steroidogenesis inhibitors and pituitary-directed therapies in patients with CS was primarily evaluated by the normalization of cortisol secretion per UFC (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationTreatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953 · cited 4×
“However, up to onethird of patients do not achieve sustained remission after pituitary surgery and require additional treatment (3, 5).”
BackgroundInfluentialSelf-citationTreatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641 · cited 1×
“Prolonged exposure to elevated cortisol levels is associated with substantial morbidity and mortality and impaired quality of life (QoL) (1-3).”
BackgroundThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Daniel, E., Aylwin, S., Mustafa, O., Ball, S., Munir, A., Boelaert, K., Chortis, V., Cuthbertson, D. J., Daousi, C., Rajeev, S. P., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2616 · Cited by 231 · cited 1×
“6 years; dose schedule: 2–4 doses/day) in patients with Cushing’s syndrome (n=115/164 had Cushing’s disease), 43% of 37 patients with mUFC measurements available had normalized mUFC (17).”
BackgroundWebb, S. M., Badia, X., Barahona, M. J., Colao, A., Strasburger, C. J., Tabarin, A., van Aken, M. O., Pivonello, R., Stalla, G., Lamberts, S. W. J., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0762 · Cited by 229 · cited 1×
“12 scale for facial rubor, striae, supraclavicular fat pad, dorsal fat pad, proximal muscle wasting, abdominal obesity, and bruising; and change in health-related QoL, assessed using the Cushing’s Disease Health-Related Quality of Life Questionnaire (CushingQoL) (11) and the Beck Depression Inventory second edition (B…”
MethodPivonello, R., Fleseriu, M., Newell-Price, J., Bertagna, X., Findling, J., Shimatsu, A., Gu, F., Auchus, R., Leelawattana, R., Lee, E. J., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30240-0 · Cited by 222
Self-citation(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n49 · Cited by 190
Cushing’s disease: the burden of illness
Pivonello, R., De Martino, M. C., De Leo, M., Simeoli, C., & Colao, A. (2017) · Endocrine · doi:10.1007/s12020-016-0984-8 · Cited by 171 · cited 1×
“22 and metabolic and skeletal disorders (13).”
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
Lacroix, A., Gu, F., Gallardo, W., Pivonello, R., Yu, Y., Witek, P., Boscaro, M., Salvatori, R., Yamada, M., Tauchmanova, L., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30326-1 · Cited by 162 · cited 1×
“pasireotide normalized mUFC in 35% of patients at 12 months (18).”
BackgroundSelf-citationPetersenn, S., Beckers, A., Ferone, D., van der Lely, A., Bollerslev, J., Boscaro, M., Brue, T., Bruzzi, P., Casanueva, F. F., Chanson, P., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0883 · Cited by 156
Fleseriu, M., Pivonello, R., Elenkova, A., Salvatori, R., Auchus, R. J., Feelders, R. A., Geer, E. B., Greenman, Y., Witek, P., Cohen, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30313-4 · Cited by 101 · cited 3×
“The Phase III study of levoketoconazole in patients with Cushing’s syndrome reported normal latenight salivary cortisol levels in four patients (N=94) after 6 months of treatment (14).”
BackgroundResultSelf-citationEffectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis
Broersen, L. H. A., Jha, M., Biermasz, N. R., Pereira, A. M., & Dekkers, O. M. (2018) · Pituitary · doi:10.1007/s11102-018-0897-z · Cited by 100 · cited 1×
“Options for these patients include repeat pituitary surgery, medical therapy, radiation therapy, and bilateral adrenalectomy (3, 6).”
BackgroundMetyrapone treatment in Cushing’s syndrome: a real-life study
Ceccato, F., Zilio, M., Barbot, M., Albiger, N. M. E., Antonelli, G., Plebani, M., Watutantrige‐Fernando, S., Sabbadin, C., Boscaro, M., & Scaroni, C. M. (2018) · Endocrine · doi:10.1007/s12020-018-1675-4 · Cited by 79
Quality of Life in Patients With Cushing's Disease
Vives, A. S., Resmini, E., Martínez-Momblán, M.-A., Valassi, E., Martel‐Duguech, L., & Webb, S. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00862 · Cited by 76 · cited 8×
“Other secondary endpoints included: proportion of patients with mUFC ≤ULN or >ULN but ≥50% redu tion from baseline at weeks 12, 36, and 48; time to first control of mUFC; mUFC changes during the core period; change from baseline in serum and salivary cortisol levels; change from baseline to weeks 12, 36, and 48 in car…”
BackgroundInfluentialFleseriu, M., Hamrahian, A. H., Hoffman, A. R., Kelly, D. F., & Katznelson, L. (2016) · Endocrine Practice · doi:10.4158/ep161512.dscr · Cited by 68
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease
Newell-Price, J., Pivonello, R., Tabarin, A., Fleseriu, M., Witek, P., Gadelha, M. R., Petersenn, S., Tauchmanova, L., Ravichandran, S., Gupta, P., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0695 · Cited by 60 · cited 1×
“24 Previous research in patients with Cushing’s disease taking pasireotide showed that patients who achieved normalization of both mUFC and late-night salivary cortisol levels had better clinical outcomes than those who only had normal mUFC (19).”
BackgroundSelf-citationNieman, L. K., Boscaro, M., Carla, S., et al. (2021) · Endocrine Abstracts · doi:10.1530/endoabs.73.oc3.3 · Cited by 3 · cited 1×
“However, in other prospective trials of steroidogenesis inhibitors in patients with Cushing’s syndrome, the cortisol-normalization rate was 31% after 6 months of levoketoconazole (n=80/94 had Cushing’s disease) (14) and 49% after 36 weeks of metyrapone (n=44/49 had Cushing’s disease; e-ECE 2021 abstract) (16).”
Background
Research works printed but not linked: 1
- Nieman, 2021, Metyrapone treatment in endogenous Cushing’s syndrome, abst OC3.3
Cited by
Reincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 256
Gadelha, M., Gatto, F., Wildemberg, L. E., & Fleseriu, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01961-x · Cited by 168
Self-citationDormoy, A., Haissaguerre, M., Vitellius, G., Cao, C. D., Geslot, A., Drui, D., Lasolle, H., Vieira-Pinto, O., Salenave, S., François, M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac691 · Cited by 82
An individualized approach to the management of Cushing disease
Fleseriu, M., Varlamov, E. V., Hinojosa‐Amaya, J. M., Langlois, F., & Melmed, S. K. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00868-7 · Cited by 80
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension
Fleseriu, M., Newell-Price, J. D. C., Pivonello, R., Shimatsu, A., Auchus, R. J., Scaroni, C. M., Belaya, Z. E., Feelders, R. A., Vila, G., Houde, G., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0317 · Cited by 78
Self-citation
Metadata
- Authors
- Gadelha, M., Bex, M., Feelders, R. A., Heaney, A. P., Auchus, R. J., Gilis-Januszewska, A., Witek, P., Belaya, Z., Yu, Y., Liao, Z., Ku, C. H. C., Carvalho, D., Roughton, M., Wojna, J., Pedroncelli, A. M., & Snyder, P. J.
- Affiliations
- Universidade Federal do Rio de Janeiro (BR)
- Universitair Ziekenhuis Leuven (BE)
- Erasmus MC (NL)
- University of California, Los Angeles (US)
- University of Michigan (US)
- Department of Endocrinology, Jagiellonian University Medical College , Kraków , Poland
- Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw , Warsaw , Poland
- Endocrinology Research Center (RU)
- West China Hospital of Sichuan University (CN)
- Sun Yat-sen University (CN)
- Clinica Los Yoses , San Pedro , Costa Rica
- Universidade do Porto (PT)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- Recordati AG , Basel , Switzerland
- University of Pennsylvania (US)
- Corresponding author
- Gadelha, Mônica
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2022-03-23
- Volume
- 107
- Issue
- 7
- Pages
- e2882-e2895
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC9202723
- OpenAlex
- W4220667260
- Semantic Scholar
- 71c848803fb3dd5777e985b42b03be3daabfc26c
- Cited by
- 114
- References
- 19
- Citations by year
- 2026: 24 · 2025: 38 · 2024: 18 · 2023: 22 · 2022: 12
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company
- Pfizer
- Neurocrine Biosciences
- Quest Diagnostics
- Recordati Rare Diseases
- Novo Nordisk
- H. Lundbeck A/S
- Ipsen
- Novartis Pharma
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- Cushing's disease, osilodrostat, 11β-hydroxylase inhibitor, hypercortisolism, cortisol suppression, urinary free cortisol, drug safety, adverse events, open-label extension, treatment efficacy, joint pain, appetite loss, nausea
- MeSH terms
- Adult, Double-Blind Method, Humans, Hydrocortisone, Imidazoles, Pyridines, Treatment Outcome, Pituitary ACTH Hypersecretion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.